MedPage Today on MSN2d
Sotatercept Helps the Sickest Patients With Pulmonary Arterial Hypertension
Adding sotatercept (Winrevair) to the treatment regimen for pulmonary arterial hypertension (PAH) in high-risk patients ...
Experts Set International And Multidisciplinary Collaboration As Priorities In Pulmonary Hypertension Management - AETOS...
The seventh edition of the International Meeting on Pulmonary Hypertension Clinical Treatment (IMPAHCT), organized by the pharmaceu ...
Experts Set International and Multidisciplinary Collaboration As Priorities in Pulmonary Hypertension Management
The seventh edition of the International Meeting on Pulmonary Hypertension Clinical Treatment (IMPAHCT), organized by the ...
Verywell Health on MSN6d
7 Common Causes of Pulmonary Arterial Hypertension
Pulmonary arterial hypertension is caused by narrowing of the blood vessels in the lungs. Learn how it happens, including ...
Mirage News3d
Experts Prioritize Global Collaboration in Pulmonary Hypertension
The seventh edition of the International Meeting on Pulmonary Hypertension Clinical Treatment (IMPAHCT), organized by ...
Managed Healthcare Executive3d
Winrevair Shows Promise in Advancing PAH Treatment | ACC 2025
Marc Humbert, M.D., Ph.D., professor of respiratory medicine at Université Paris-Saclay and Inserm, believes that recent ...
Fierce Pharma3d
Merck's Winrevair slashes mortality-morbidity risk by 76%
The interim results of a phase 3 trial of Merck’s pulmonary arterial hypertension (PAH) treatment Winrevair were so ...
Applied Clinical Trials Online2d
Merck Shares Results from Phase III Clinical Trial of Winrevair in Pulmonary Arterial Hypertension
Winrevair (sotatercept-csrk), compared to placebo, reduced the risk of all-cause death, lung transplantation, and hospitalization.
The American Journal of Managed Care3d
ZENITH Trial Findings Could Reshape PAH Treatment, Extending Sotatercept’s Reach
Another study testing sotatercept as an early intervention for pulmonary arterial hypertension (PAH) is anticipated to ...
The American Journal of Managed Care3d
Sotatercept Reduces Risk of Death, Transplant, or Hospitalization in Advanced PAH
Patients taking sotatercept had a 76% relative risk reduction in morbidity and mortality events compared with patients taking ...
Sotatercept FAERS study highlights emerging safety signals in PAH treatment
The study emphasised a higher incidence of AEs in elderly patients (65–85 years), highlighting the need for vigilant ...